Baseline-adjusted comparative study shows that dosing time is not critical for efficacy in moderate-to-severe allergic rhinitis.
Once-daily intranasal mometasone furoate provides comparable clinical benefits regardless of whether it is administered in the morning or in the evening in patients with moderate-to-severe SAR. These findings suggest that dosing time has limited clinical relevance for long-acting intranasal corticosteroids, allowing treatment to be guided by patient preference without compromising efficacy.
No takes yet. Share an insight, caveat, or question.
Ünlü et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: